OPERATING RESPONSIBLY

ENVIRONMENTAL, SOCIAL & GOVERNANCE (ESG)

ESG is critical to achieving our core objectives and delivering value to our patients, communities, employees, partners and shareholders, and involves the full commitment from Celadon’s executive team.

Slide 1
ENVIRONMENTAL

UK domestic production: The UK market is currently reliant on imports from overseas. By investing in production at our state of the art UK facility, we are reducing the sector’s carbon footprint through reduced freight, logistics and transport.

Indoor cultivation optimising yields: Our indoor hydroponic growing system produces a higher yield, less wastage and more careful management of water when compared to outdoor and greenhouse cultivation methods.

Clean energy consumption: While cultivation is energy-intensive today, the business invested in early 2023 to supply its UK facility fully from renewable energy and is currently exploring on-site renewable energy generation options.

Slide 2
SOCIAL
QUALITY OF LIFE

There are currently over 20m chronic pain suffers in the UK. Celadon’s purpose is to improve the quality of life for patients most in need in society through alternative cannabis-based treatments.

A SAFER OPTION

With 1.4m UK patients currently using the black market for cannabis for medicinal purposes, Celadon provides a safe, regulated and value for money alternative cannabis treatment.

IMPROVING ACCESS

Our MHRA conditionally approved medical cannabis trial outcome aims for reimbursement
from the NHS to increase access
to treatment
for patients across society.

INVESTMENT IN OUR PEOPLE

Celadon is a responsible employer, investing in the development and wellbeing of our people. With comprehensive benefits, an employee share scheme, and our dedicated apprenticeship programme we take employee engagement and retention seriously.

REDUCED HARM

Our treatments aim to become an alternative to opioid based drugs with adverse side effects including addition and overdoses, currently used to treat chronic pain.

OPEN CULTURE

We operate a flat management structure with an inclusive and collaborative ethos underpinned by respect, trust and integrity as core values we hold ourselves accountable to when working with our colleagues, customers, suppliers and partners.

Slide 3
GOVERNANCE

Corporate Governance: Celadon is listed on the AIM market of the London Stock Exchange and compliant with the QCA Corporate Governance Code.

Board of Directors: The executive team comprises of seven highly experienced and diverse plc directors, four of whom are independent non-executive directors responsible for the oversight of strategy, operations, financial accounts and risk
management systems.

previous arrow
next arrow

ENVIRONMENTAL

UK domestic production: The UK market is currently reliant on imports from overseas. By
investing in production at our state of the art UK facility, we are reducing the sector’s
carbon footprint through reduced freight, logistics and transport.

Indoor cultivation optimising yields: Our indoor hydroponic growing system, produces a
higher yield, less wastage and more careful management of water when compared to
outdoor and greenhouse cultivation methods.

Reducing energy consumption: While cultivation is energy-intensive today, our
investment in new technologies and innovation including ultra-efficient LED lighting and
off-peak growing, alongside constant reviews of renewable energy options, is optimising
our production methods and reducing energy consumption

SOCIAL

QUALITY OF LIFE

There are currently over 20m chronic pain suffers in the UK. Celadon’s purpose is to improve the quality of life for patients most in need in society through alternative cannabis-based treatments.

IMPROVING ACCESS

Our MHRA conditionally approved medical cannabis trial outcome aims for reimbursement from the NHS to increase access to treatment for patients across society.

REDUCED HARM

Our treatments aim to become an alternative to opioid based drugs with adverse side effects including addition and overdoses, currently used to treat chronic pain.

A SAFER OPTION

With 1.4m UK patients currently using the black market for cannabis for medicinal purposes, Celadon provides a safe, regulated and value for money alternative cannabis treatment.

INVESTMENT IN OUR PEOPLE

Celadon is a responsible employer, investing in the development and wellbeing of our people. With comprehensive benefits, an employee share scheme, and our dedicated apprenticeship programme we take employee engagement and retention seriously.

OPEN CULTURE

We operate a flat management structure with an inclusive and collaborative ethos underpinned by respect, trust and integrity as core values we hold ourselves accountable to when working with our colleagues, customers, suppliers and partners.

GOVERNANCE

Corporate Governance: Celadon is listed on the AIM market of the London Stock Exchange and compliant with the QCA Corporate Governance Code.

Board of Directors: The executive team comprises of seven highly experienced and diverse plc directors, four of whom are independent non-executive directors responsible for the oversight of strategy, operations, financial accounts and risk
management systems.

As a UK Pharmaceutical company aiming to develop medicines that might be re-imbursed on the UK’s National Health Service (NHS), Celadon will work to align with the NHS’s requirement that by 2027 suppliers report emissions and publish a carbon reduction plan aligned with its 2045 net zero targets.

 

ENVIRONMENT

Celadon uses a highly controlled indoor cultivation environment in order to produce plants to the tightest pharmaceutical tolerances and cannabinoid content. Hydroponics is used to grow plants in a soilless substrate, with mineral salts dissolved into high quality filtered water and delivered direct to the roots of the plant. Micro-zoned sensors monitor every aspect of the environment in real time; from the room’s temperature, lighting cycles and humidity, to the plant’s mineral absorption and transpiration rates. This allows Celadon to build a data bank of optimal growing conditions for each strain, as well as adjust the room automatically.

TRACKING

Celadon has a bespoke “track and trace” system throughout the production process, providing complete transparency. Each plant is given a unique QR code, allowing it to be traced from its origins through to the final product. IOT boxes are used to automatically feed data into the system, from environmental data to the product’s weight, at each stage of production. This provides full visibility over the production process, as well as inventory tracking and accurate cost analysis which feeds into our accounting systems.

This will close in 0 seconds

Medical Cannabis Market, Transparency Market Research May 2022

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

 

ENVIRONMENT

Celadon uses a highly controlled indoor cultivation environment in order to produce plants to the tightest pharmaceutical tolerances and cannabinoid content. Hydroponics is used to grow plants in a soilless substrate, with mineral salts dissolved into high quality filtered water and delivered direct to the roots of the plant. Micro-zoned sensors monitor every aspect of the environment in real time; from the room’s temperature, lighting cycles and humidity, to the plant’s mineral absorption and transpiration rates. This allows Celadon to build a data bank of optimal growing conditions for each strain, as well as adjust the room automatically.

TRACKING

Celadon has a bespoke “track and trace” system throughout the production process, providing complete transparency. Each plant is given a unique QR code, allowing it to be traced from its origins through to the final product. IOT boxes are used to automatically feed data into the system, from environmental data to the product’s weight, at each stage of production. This provides full visibility over the production process, as well as inventory tracking and accurate cost analysis which feeds into our accounting systems.

This will close in 0 seconds

Legalised in 2018

This will close in 0 seconds

Legalised in 37 States Limited Federal legalisation

This will close in 0 seconds

Legalised in 2016

This will close in 0 seconds

Legalised in 2016

This will close in 0 seconds

Legalised in 2016 Rapid growth to >200k patients (2019-21)

This will close in 0 seconds

Legalised in 2001

This will close in 0 seconds

BUSINESS DESCRIPTION

 

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism.

Its 100,000 sq. ft UK facility operates to an EU-GMP standard and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. The Company's subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.

This will close in 0 seconds

COUNTRY OF INCORPORATION/OPERATION

 

Celadon Pharmaceuticals Plc is incorporated in England and Wales and is listed solely on the London Stock
Exchange Alternative Investment Market (AIM), and is subject to the UK City Code on Takeovers and Mergers.

TIDM: CEL.L
ISIN: GB00BDQYGP38

There are no restrictions on the transfer of Celadon Pharmaceutical’s shares.

This will close in 0 seconds

AIM SECURITIES IN ISSUE

 

The following information is correct as at 29th September 2023.

The Company’s issued share capital comprises

61,669,773 ordinary shares

Each with a nominal value of 1 pence

So far as the Company is aware, 44.47% of its issued share capital is not in public hands.

This will close in 0 seconds

Scroll to Top